← FDA DRUG APPROVALS

FDA ANDA · ANDA205654

MESALAMINE

Sponsor: ACTAVIS MID ATLANTIC

APPLICATION
ANDA205654
TYPE
ANDA
ORIGINAL APPROVAL
2020-08-14
LATEST ACTION
2025-06-17
ROUTE
RECTAL
DOSAGE FORM
SUPPOSITORY
MARKETING STATUS
Prescription

Products

MESALAMINEPrescription
MESALAMINE 1GM · SUPPOSITORY · RECTAL

Approval history

2025-06-17Labeling · Supplement 6 · standardAP
2024-08-22Labeling · Supplement 4 · standardAP
2024-08-22Labeling · Supplement 3 · standardAP
2024-08-22Labeling · Supplement 1 · standardAP
2020-08-14UNKNOWN · Original · standardAP
VIEW ON DRUGS@FDA ↗

Related on SPEQ

Pharma industryGMP disciplineFDA drug shortagesFDA enforcement & recalls

Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.

Weekly Briefing

Get the Weekly GxP Briefing

Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.

Read a past issue →